Immunogenicity of a 23-valent pneumococcal polysaccharide vaccine among Mexican children.

Sara Elva Espinosa-Padilla, Chiharu Murata, Sergio Estrada-Parra, Leopoldo Santos-Argumedo, Cesar Mascareñas, Carlos Franco-Paredes, Francisco Javier Espinosa-Rosales

Immunodeficiency Research Unit, National Institute of Pediatrics, Mexico City, Mexico.

Archives of medical research 2012 Jul

filter terms:

Streptococcus pneumoniae infection continues to be a major source of morbidity and mortality in children in Mexico. The aim of this study was to evaluate the immune response to six serotypes in children <5 years of age after immunization with a 23-valent pneumococcal polysaccharide vaccine. A prospective study was conducted among children aged from 18 months to 4 years. Pre- and postvaccination titers for the serotypes selected in this project demonstrate a substantial response among all age groups. We identified mild adverse events in 62% of the participants in this study. No serious adverse events were reported during the study. Pneumococcal polysaccharide vaccine produced adequate immunogenicity in all age groups evaluated. Copyright © 2012 IMSS. Published by Elsevier Inc. All rights reserved.

Citation

Sara Elva Espinosa-Padilla, Chiharu Murata, Sergio Estrada-Parra, Leopoldo Santos-Argumedo, Cesar Mascareñas, Carlos Franco-Paredes, Francisco Javier Espinosa-Rosales. Immunogenicity of a 23-valent pneumococcal polysaccharide vaccine among Mexican children. Archives of medical research. 2012 Jul;43(5):402-5